Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising combo for tough blood cancers hits early snag

NCT ID NCT04809467

Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of two targeted drugs, tafasitamab and parsaclisib, in 54 adults with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia. The goal was to see if the combination was safe and could shrink tumors. However, the trial was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tafasitamab (a targeted antibody) and parsaclisib (a targeted pill)
What this could lead to
If successful, this combination could offer a new treatment option for people with blood cancers that have stopped responding to standard therapies.
What could go wrong
This was a very early (Phase 1b/2a) trial that was terminated early, so we don't know if the combination is safe or effective. Side effects from these drugs can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

54 people

The number who actually took part.

Started

Sep 2021

Finished

Oct 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed R/R B-cell malignancy: DLBCL (THRLBCL, EBV-positive DLBCL of the elderly, Grade 3b FL, HGBL with MYC and BCL2 and/or BCL6 rearrangements, transformed lymphoma); MCL ((with cyclin D1 overexpression or t(11;14); FL (Grade 1, 2, 3a); MZL (extranodal, nodal, splenic) ; CLL, or SLL * Willingness to undergo biopsy * At least 2 prior systemic treatment regimens, including prior treatment with an anti-CD20 antibody (all cohorts) or prior treatment with a BTK inhibitor (CLL/SLL) * Relapsed, progressive, or refractory NHL or CLL * For NHL/SLL: Radiographically measurable nodal or extranodal disease (all cohorts except CLL) * ECOG-PS 0 - 2 * LVEF ≥ 50% * Adequate renal, hepatic, bone marrow function Exclusion Criteria: * Any other histological type of lymphoma * Primary or secondary CNS lymphoma * Anticancer and/or investigational therapy within the past 30 days or 5 half-lives * Allogeneic stem cell transplantation within the past 6 months, or ASCT within 3 months before C1D1 * Previous treatment with CD19-targeted therapy or PI3K inhibitors * Clinically significant cardiac disease * Other malignancy within the past 3 years * Active graft-versus-host disease * Stroke or intracranial hemorrhage within the past 6 months * Chronic or current active infectious disease * Positive virus serology for HCV, HBV, HIV * Currently pregnant or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic lymphocytic leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia leukemia non-Hodgkin lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic lymphocytic leukemia Non-Hodgkin lymphoma

Contacts and locations

Locations

  • AZ DELTA

    Roeselare, 08800, Belgium

  • Az Groeninge Campus Kennedylaan

    Kortrijk, 08500, Belgium

  • Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello

    Palermo, 90146, Italy

  • Azienda Ospedaliero Universitaria Pisana

    Pisa, 56126, Italy

  • Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

    Milan, 20162, Italy

  • Cancer Center For Blood Disorders

    Bethesda, Maryland, 20817, United States

  • Centre Henri Becquerel

    Rouen, 76038, France

  • Centre Hospitalier Universitaire de Nantes (Chu de Nantes) - Hotel-Dieu

    Nantes, 44093, France

  • Centro Integral Oncologico Clara Campal (Ciocc)

    Madrid, 28050, Spain

  • Clinical Research Alliance

    New Hyde Park, New York, 11042, United States

  • Community Health Network, Inc.

    Indianapolis, Indiana, 46250, United States

  • Fondazione Irccs Istituto Nazionale Dei Tumori

    Milan, 20133, Italy

  • Grand Hospital de Charleroi

    Charleroi, 06000, Belgium

  • Hanusch-Krankenhaus Der Wiener Gebietskrankenkasse

    Vienna, 01140, Austria

  • Hopital Sant Pau

    Barcelona, 08036, Spain

  • Hospital Clinico Universitario de Salamanca

    Salamanca, 37007, Spain

  • Hospital General Universitario Vall D Hebron

    Barcelona, 08035, Spain

  • Hospital General Universitario de Valencia

    Valencia, 46014, Spain

  • Hospital General Unviersitario de Alicante

    Alicante, 03010, Spain

  • Hospital Puerta de Hierro

    Majadahonda, 28222, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario Central de Asturias

    Oviedo, 33011, Spain

  • Hospital Universitario Marques de Valdecilla

    Santander, 39008, Spain

  • Hospital Universitario Quironsalud Madrid

    Madrid, 28223, Spain

  • Hospital Universitario San Cecilio

    Granada, 18016, Spain

  • Hospital Universitario Virgen Del Rocio

    Seville, 41015, Spain

  • Ico Institut Catala D Oncologia

    Barcelona, 08908, Spain

  • Indiana Blood and Marrow Transplantation

    Indianapolis, Indiana, 46237, United States

  • Institut Gustave Roussy

    Villejuif, 94805, France

  • Institut Jules Bordet

    Brussels, B-1070, Belgium

  • Irccs Istituto Clinico Humanitas

    Rozzano, 20089, Italy

  • Istituto Nazionale Tumori Irccs Fondazione Pascale

    Naples, 80131, Italy

  • Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori

    Meldola, 47014, Italy

  • Jefferson University Hospitals

    Philadelphia, Pennsylvania, 19107, United States

  • Justus-Liebig University

    Giessen, 35392, Germany

  • Landeskrankenhaus Salzburg

    Salzburg, 05020, Austria

  • Norton Cancer Institute

    Louisville, Kentucky, 40202, United States

  • Ohio State University

    Columbus, Ohio, 43210, United States

  • Ordensklinikum Linz Gmbh Elisabethinen

    Linz, A-4020, Austria

  • Ospedale Santa Maria Delle Croci

    Ravenna, 48121, Italy

  • S Orsolas University Hospital Seragnoli Institute of Hematology

    Bologna, 40138, Italy

  • Universitair Ziekenhuis (Uz) Leuven

    Leuven, 03000, Belgium

  • Universitair Ziekenhuis Antwerpen (Uza)

    Edegem, 02650, Belgium

  • Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii

    Mainz, 55131, Germany

  • University Hospital Brest

    Brest, 29609, France

  • University Hospital Wurzburg

    Würzburg, 97080, Germany

  • University Medical Center Freiburg

    Freiburg im Breisgau, 79106, Germany

  • University of Alabama At Birmingham Comprehensive Cancer Center

    Birmingham, Alabama, 35205, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • University of Southern California

    Los Angeles, California, 90089, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.